Diazoxide Choline

Brand names: Vykat Xr · Active ingredient: Diazoxide Choline

In short: VYKAT XR is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS).

Forms & strengthsExtended-release tablets: VYKAT XR 25­mg of diazoxide choline: white, capsule-shaped, film-coated, waxed tablets, debossed with S-25 on one side. …
LabelSoleno Therapeutics, Inc.
Label updatedApr 10, 2025

What is Diazoxide Choline used for?

VYKAT XR is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS).

Diazoxide Choline dosage

Laboratory Testing Prior to VYKAT XR Initiation

Prior to initiating treatment with VYKAT XR, test fasting plasma glucose (FPG) and HbA1c and optimize blood glucose in patients who have hyperglycemia .

For fasting glucose and HbA1c monitoring recommendations during VYKAT XR treatment and for dosage modifications based on results, see Dosage and Administration (2.3)

.

Important Information Regarding Substitution

Do not substitute VYKAT XR with diazoxide oral suspension because the pharmacokinetic profiles are different .

Administer VYKAT XR orally with or without food once daily .

Swallow tablets whole. Do not split, crush, or chew the extended-release tablets because doing so may compromise the extended-release characteristics, efficacy, or safety of VYKAT XR.

The recommended oral dosage of VYKAT XR is based on body weight. The recommended starting dosage and titration schedule of VYKAT XR are shown in Table 1.

Weight | Recommended Once Daily Dosage

Starting Dosage | Titration Dosage | Titration Dosage | TargetMaintenanceDose

Weeks 1 and 2 | Weeks 3 and 4 | Weeks 5 and 6

20 kg to <30 kg | 25 mg | 50 mg | 75 mg | 100 mg

30 kg to <40 kg | 75 mg | 150 mg | 150 mg | 150 mg

40 kg to <65 kg | 75 mg | 150 mg | 225 mg | 225 mg

65 kg to <100 kg | 150 mg | 225 mg | 300 mg | 375 mg

100 kg to <135 kg | 150 mg | 300 mg | 375 mg | 450 mg

≥135 kg | 150 mg | 300 mg | 450 mg | 525 mg

The maximum recommended dosage of VYKAT XR is 5.8 mg/kg/day or 525 mg per day. Dosages above 5.8 mg/kg/day or 525 mg per day have not been evaluated in patients with PWS.

Elevations in Fasting Glucose or HbA1c

After initiating treatment with VYKAT XR, monitor:

Fasting glucose (FPG or fasting blood glucose) at least once every week for the first 2 weeks, then at least once every 4 weeks, and as clinically indicated.

HbA1c every 3 months and as clinically indicated.

Monitor fasting glucose more frequently during the first few weeks of VYKAT XR treatment in patients with risk factors for hyperglycemia.

If clinically significant elevations in fasting glucose of HbA1c occur during treatment, temporarily interrupt VYKAT XR or reduce the dosage until glycemic parameters are appropriately managed. Consider initiation or adjustment of standard antidiabetic therapy(ies). If clinically significant glucose elevations are noted during titration, titrate over a longer duration and/or to a lower dosage .

Fluid Overload

Monitor for signs or symptoms of edema or fluid overload. Consider dosage reduction or temporary dosage interruption in the event of clinically significant fluid overload. If clinically significat fluid overload is noted during titration, titrate over a longer duration and/or to a lower dosage . …

How to take Diazoxide Choline — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Administration Instructions

Advise patients to swallow tablets whole and not to split, crush, or chew VYKAT XR .

Hyperglycemia

Advise the patient or caregiver that VYKAT XR can cause hyperglycemia, sometimes leading to diabetic ketoacidosis, and that the patient will have monitoring of blood glucose before and during VYKAT XR treatment. Advise patients or caregivers on the signs and symptoms of hyperglycemia (e.g., excessive thirst, urinating more often than usual or higher amount of urine than usual, or increased appetite with weight loss) and ketoacidosis (e.g., nausea, vomiting, abdominal pain, generalized malaise and shortness of breath) and to contact their healthcare provider if these signs or symptoms occur .

Risk of Fluid Overload

Advise the patient or caregiver that VYKAT XR may cause edema, including severe adverse reactions associated with fluid overload. Advise patients or caregivers on the signs and symptoms of edema and to contact their healthcare provider if signs or symptoms of edema occur . …

Warnings & precautions

Do not take this medicine if: VYKAT XR is contraindicated in patients with known hypersensitivity to diazoxide, other components of VYKAT XR, or to thiazides. Erythema multiforme has been reported with VYKAT XR .

VYKAT XR increases blood glucose, due primarily to an inhibition of insulin release from the pancreas. Hyperglycemia, including severe adverse reactions associated with diabetic ketoacidosis, occurred in VYKAT XR-treated patients during clinical trials .

Precipitating conditions for diabetic ketoacidosis may include reduction in the dosages of concomitant antihyperglycemic medications, increase in the dosages of concomitant growth hormone, intercurrent illness, surgery, volume depletion or alcohol abuse. Signs and symptoms of ketoacidosis include nausea, vomiting, abdominal pain, generalized malaise and shortness of breath.

Before initiating VYKAT XR, test fasting plasma glucose (FPG) and HbA1c; optimize blood glucose in patients who have hyperglycemia. After initiating treatment with VYKAT XR, regularly monitor fasting glucose (FPG or fasting blood glucose) and HbA1c . Monitor fasting glucose more frequently for the first few weeks of treatment with VYKAT XR in patients with risk factors for hyperglycemia, such as obesity, elevated FPG, HbA1c at the upper limit of normal or above, concomitant use of growth hormone, or concomitant use of systemic corticosteroids.

Advise patients of the signs and symptoms of hyperglycemia (e.g., excessive thirst, urinating more often than usual or higher amount of urine than usual, or increased appetite with weight loss). If a patient experiences hyperglycemia after initiating treatment with VYKAT XR, monitor fasting glucose as clinically indicated, and at least twice weekly until fasting glucose decreases to normal levels. Consider monitoring ketones in patients with worsening hyperglycemia. …

Diazoxide Choline side effects

The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling:

Hyperglycemia

Risk of Fluid Overload

Adverse Reactions from Clinical Studies of VYKAT XR in Patients with PWS

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In the clinical study development program for treatment of hyperphagia in patients aged 4 years and older with PWS, a total of 125 patients received at least 1 dose of VYKAT XR. Patients received dosages of VYKAT XR up to 5.8 mg/kg/day (up to a maximum dosage of 525 mg/day) for up to 4.86 years (median: 3.0 years) in the following studies:

Study 1: 13-week, randomized, double-blind, placebo-controlled, parallel-arm study in which 126 patients were randomized in a 2:1 ratio to VYKAT XR or placebo and received at least one dose of VYKAT XR.

Study 2-OLE: A long-term, open-label, maintenance treatment period in 115 patients (mean duration 2.6 years; maximum duration 4.3 years) who had previously been enrolled in Study 1.

Study 2-RWP: A 16-week, double-blind, placebo-controlled, randomized withdrawal treatment period, in which 77 patients who had completed Study 1 and Study 2-OLE were randomized in a 1:1 ratio to VYKAT XR or placebo . …

Drug interactions

Table 4 displays clinically significant drug interactions with VYKAT XR.

Strong CYP1A2 InhibitorsSee www.fda.gov/CYPandTransporterInteractingDrugs for examples of strong CYP1A2 and CYP3A4 inhibitors, sensitive CYP1A2 substrates, and dual strong CYP3A4 / moderate 1A2 inducers.

Prevention or Management | Reduce the dosage of VYKAT XR when concomitantly used with strong inhibitors of CYP1A2 .

Mechanism and Clinical Effect(s) | VYKAT XR is a CYP1A2 substrate. Concomitant use of VYKAT XR with strong CYP1A2 inhibitors increases exposure of diazoxide, which may increase the frequency and/or severity of adverse reactions from VYKAT XR .

CYP1A2 Substrates

Prevention or Management | Concomitant use of VYKAT XR with CYP1A2 substrates is not recommended.

Mechanism and Clinical Effect(s) | VYKAT XR is an inhibitor of CYP1A2. Concomitant use of VYKAT XR with CYP1A2 substrates increases exposure of these substrates. This may increase the frequency and/or severity of adverse reactions from such substrates.

Strong CYP3A4 Inhibitors

Prevention or Management | Monitor the frequency and severity of adverse reactions from VYKAT XR. A dosage reduction of VYKAT XR may be needed when used concomitantly with strong CYP3A4 inhibitors. …

About this medicine

VYKAT XR contains diazoxide choline. Diazoxide choline is very slightly soluble to soluble in solvents dichloromethane, tetrahydrofuran, acetonitrile, and methanol and practically insoluble in solvents methyl tert-butyl ether. The pKa is 8.44 ± 0.01

Diazoxide choline is 7-Chloro-3-methyl-1λ6, 2,4-benzothiadiazin-2-ide 1,1-dioxide 2- hydroxyethyl(trimethyl)azanium. The empirical formula is C8H6ClN2O2S•C5H14NO and the molecular weight is 333.83 g/mole. The structural formula is:

VYKAT XR is for oral administration and is available as extended-release tablets in the following strengths: 25 mg tablet contains diazoxide choline 25 mg, equivalent to 17.2 mg diazoxide; 75 mg tablet contains diazoxide choline 75 mg, equivalent to 51.6 mg diazoxide; and 150 mg tablet contains diazoxide choline 150 mg, equivalent to 103.2 mg diazoxide. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 0e745e85-9512-e360-e063-6394a90aebf1. Read the full official label on DailyMed.